Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand

Reuters

Nov 03

Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand

Overview

Bruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy decline
Adjusted EPS for Q3 2025 beats consensus at $0.45, despite a decline from last year
Company lowers FY2025 guidance, citing weaker demand and EPS dilution from higher share count

Outlook

Bruker expects FY2025 revenue of $3.41 to $3.44 bln, with 1-2% growth yoy
Company forecasts FY2025 non-GAAP EPS of $1.85 to $1.90
Bruker anticipates significant margin expansion and EPS growth in FY2026

Result Drivers

BOOKINGS GROWTH - Mid-single digit percentage organic bookings growth driven by academic/government and biopharma markets
PRODUCT RECEPTION - New spatial biology and proteomics solutions well-received by biopharma and academic customers
DEMAND WEAKNESS - Revenue decline due to weaker academic and research instruments demand in H1 2025

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Beat	$860.50 mln	$848.72 mln (12 Analysts)
Q3 Adjusted EPS	Beat	$0.45	$0.33 (13 Analysts)
Q3 Net Income		-$58.50 mln
Q3 Gross Profit		$379.40 mln
Q3 Operating Expenses		$431.20 mln
Q3 Operating Income		-$51.80 mln

Press Release: ID:nBw43qLnva

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580064297"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580064297\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580064297?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580064297","market":"fut","top_or_hot":-1,"title":"Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand</title></head><body><p><span>Overview</span></p><ul><li><p>Bruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy decline</p></li><li><p>Adjusted EPS for Q3 2025 beats consensus at $0.45, despite a decline from last year</p></li><li><p>Company lowers FY2025 guidance, citing weaker demand and EPS dilution from higher share count</p></li></ul><p><span>Outlook</span></p><ul><li><p>Bruker expects FY2025 revenue of $3.41 to $3.44 bln, with 1-2% growth yoy</p></li><li><p>Company forecasts FY2025 non-GAAP EPS of $1.85 to $1.90</p></li><li><p>Bruker anticipates significant margin expansion and EPS growth in FY2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BOOKINGS GROWTH - Mid-single digit percentage organic bookings growth driven by academic/government and biopharma markets</p></li><li><p>PRODUCT RECEPTION - New spatial biology and proteomics solutions well-received by biopharma and academic customers</p></li><li><p>DEMAND WEAKNESS - Revenue decline due to weaker academic and research instruments demand in H1 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$860.50 mln</p></td><td><p>$848.72 mln (12 Analysts)</p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$0.45</p></td><td><p>$0.33 (13 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$58.50 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$379.40 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$431.20 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$51.80 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw43qLnva</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand</title></head><body><p><span>Overview</span></p><ul><li><p>Bruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy decline</p></li><li><p>Adjusted EPS for Q3 2025 beats consensus at $0.45, despite a decline from last year</p></li><li><p>Company lowers FY2025 guidance, citing weaker demand and EPS dilution from higher share count</p></li></ul><p><span>Outlook</span></p><ul><li><p>Bruker expects FY2025 revenue of $3.41 to $3.44 bln, with 1-2% growth yoy</p></li><li><p>Company forecasts FY2025 non-GAAP EPS of $1.85 to $1.90</p></li><li><p>Bruker anticipates significant margin expansion and EPS growth in FY2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BOOKINGS GROWTH - Mid-single digit percentage organic bookings growth driven by academic/government and biopharma markets</p></li><li><p>PRODUCT RECEPTION - New spatial biology and proteomics solutions well-received by biopharma and academic customers</p></li><li><p>DEMAND WEAKNESS - Revenue decline due to weaker academic and research instruments demand in H1 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$860.50 mln</p></td><td><p>$848.72 mln (12 Analysts)</p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$0.45</p></td><td><p>$0.33 (13 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$58.50 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$379.40 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$431.20 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$51.80 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw43qLnva</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRKR","symbol_name":"布鲁克","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL1N3WF0DO:1","article_id":"2580064297","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580064297","pubTimestamp":1762171858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demandOverviewBruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy declineAdjusted EPS fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRKR":"布鲁克","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4121":"生命科学工具和服务"},"translate_title":"科学仪器制造商布鲁克第三季度超出预期，因需求疲软而下调财年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRKR":0.9},"content_text":"Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demandOverviewBruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy declineAdjusted EPS for Q3 2025 beats consensus at $0.45, despite a decline from last yearCompany lowers FY2025 guidance, citing weaker demand and EPS dilution from higher share countOutlookBruker expects FY2025 revenue of $3.41 to $3.44 bln, with 1-2% growth yoyCompany forecasts FY2025 non-GAAP EPS of $1.85 to $1.90Bruker anticipates significant margin expansion and EPS growth in FY2026Result DriversBOOKINGS GROWTH - Mid-single digit percentage organic bookings growth driven by academic/government and biopharma marketsPRODUCT RECEPTION - New spatial biology and proteomics solutions well-received by biopharma and academic customersDEMAND WEAKNESS - Revenue decline due to weaker academic and research instruments demand in H1 2025Key DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueBeat$860.50 mln$848.72 mln (12 Analysts)Q3 Adjusted EPSBeat$0.45$0.33 (13 Analysts)Q3 Net Income-$58.50 mlnQ3 Gross Profit$379.40 mlnQ3 Operating Expenses$431.20 mlnQ3 Operating Income-$51.80 mlnPress Release: ID:nBw43qLnvaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}